McDonald's Corp vs GeneDx Holdings Corp — how do they compare? McDonald's Corp trades at $273.97 (market cap $194.00B), while GeneDx Holdings Corp trades at $81.98 (market cap $2.44B). The key difference: McDonald's Corp is far larger — about 79.5× GeneDx Holdings Corp's market cap, and McDonald's Corp pays a 2.71% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MCD | WGS | |
|---|---|---|
Market Cap | $194.00B | $2.44B |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $341.06 | $167.51 |
52-Week Low | $262.80 | $34.51 |
Enterprise Value | $247.77B | $2.48B |
Dividend Yield | 2.71% | — |
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $274.15, down slightly by 0.12% on the day, with technical indicators showing a neutral overall signal. The company demonstrates strong fundamentals with consistent revenue growth, reaching $26.89 billion in 2025, and robust profitability with a 31.72% net income margin. Recent earnings have consistently beaten expectations, and the company has announced a new global growth strategy focused on automation and menu innovation to drive future performance.
The outlook for MCD is positive, supported by strong analyst consensus with a $322.45 price target implying significant upside. Key opportunities include the successful execution of its new growth plan and its defensive qualities in a challenging economy. Primary risks involve inflationary pressures on franchisee margins and intense competition in the quick-service restaurant sector.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →